Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

The researchers investigated whether changes in retinal oxygenation, retinal vascular autoregulation, and central retinal thickness are altered by semaglutide, empagliflozin or the combination.

Who Took Part

The abstract describes 120 participants taking part.

By PubMed's age tags, the people studied were middle-aged adults.

A total of 120 participants with type 2 diabetes, established or high risk of cardiovascular disease and age ≥50 years were randomised into four parallel groups (semaglutide, empagliflozin, the combination or tablet placebo, n = 30 for each group).

How the Study Was Run

In design terms this was a randomized, open-label, placebo-controlled and parallel-group study.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

Groups ran in parallel: each of the participants stayed in one arm throughout.

This study was a prespecified, secondary outcome from a randomised, 32 weeks partly placebo-controlled, partly open-label, clinical trial on the effects of semaglutide and empagliflozin on arterial stiffness and kidney oxygenation.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Hypoglycemic Agents, Retina, Semaglutide, Benzhydryl Compounds and Glucosides.

The authors tagged it with the keywords Diabetic retinopathy, Glucagon-like peptide 1 receptor agonist, Oximetry and Sodium-glucose transporter 2 inhibitors.

What This Means in Plain Language

The paper is a randomized, open-label and placebo-controlled study of Semaglutide in 120 participants.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Journal of diabetes and its complications), a journal based in United States.

More context: the Semaglutide compound page, all human trials.